IC
CTMX icon

Ikarian Capital’s CytomX Therapeutics CTMX Stock Holding History

Ikarian Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,172,616
Closed -$13.5M – 181
2025
Q4 		$13.5M Sell
3,172,616
-200,000
-6% -$760K 1.06% 27
2025
Q3 		$10.8M Buy
+3,372,616
New +$7.6M 1.09% 23
2025
Q1 		– Sell
-8,924
Closed -$9.19K – 183
2024
Q4 		$9.19K Hold
8,924
– – ﹤0.01% 167
2024
Q3 		$10.5K Hold
8,924
– – ﹤0.01% 144
2024
Q2 		$10.9K Buy
+8,924
New +$17.8K ﹤0.01% 113

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital's CTMX Position: Q1 2026 in Review

Ikarian Capital sold out of CytomX Therapeutics (CTMX) in Q1 2026, closing a stake of 3,172,616 shares — an estimated $13.5M sold.

Ikarian Capital first reported a position in CTMX in Q2 2024 and held it in 5 quarters. The position peaked at $13.5M in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Ikarian Capital reported no remaining CytomX Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 3,172,616 CytomX Therapeutics shares in Q1 2026, an estimated $13.5M.
  • Ikarian Capital first reported a position in CytomX Therapeutics in Q2 2024 and held it in 5 quarters.
  • Ikarian Capital's CytomX Therapeutics position peaked at $13.5M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.